No Data
No Data
Chenguang Biotech (300138): Performance falls short of forecast, the central plant extraction business performed steadily
On April 24, 2024, Chenguang Biotech released its results report for the first quarter of 2024. Key investment points Q1 results fall at the center of forecasting, and the scale effect is expected to dilute expenses 2024Q1, total revenue of 1,732 billion yuan (same as
Southwest Securities released a research report on April 23 stating that it gave Chenguang Biotech (300138.SZ) a purchase rating. The main reasons for the rating include: 1) the vegetable extraction business consolidates advantages, and the echelon produc
Southwest Securities released a research report on April 23 stating that it gave Chenguang Biotech (300138.SZ) a purchase rating. The main reasons for the rating include: 1) the vegetable extraction business consolidates advantages, and the echelon products continue to expand; 2) the cottonseed business is stable and the health care business is developing strongly; 3) cost control is good and profitability is under pressure; 4) diversified products continue to gain strength, and cottonseed losses are stabilizing. (Mainichi Keizai Shimbun)
Chenguang Biotech (300138.SZ) announced first-quarter results, net profit of 385.919 million yuan, a decrease of 71.42%
Chenguang Biotech (300138.SZ) released its report for the first quarter of 2024. The company's revenue was 17.3...
Chenguang Biotech (300138): Steady growth in plant extraction business revenue and pressure on profitability
23Q4 revenue was +13.5% YoY. The company achieved revenue of 6.872 billion yuan in 23 years, +9.14% year on year, net profit to mother of 480 million yuan, +10.53% year on year, net profit of 367 million yuan after deducting non-return to mother
Chenguang Biotech (300138.SZ): A total cost of 258 million yuan to buy back 4.06% of the shares
Gelonghui, April 22, 丨 Chenguang Biotech (300138.SZ) announced that as of April 19, 2024, the company had repurchased 21,648,508 shares of the company's shares through a dedicated securities account, with a transaction amount of RMB 257,655,435.24 (excluding transaction fees). The repurchased shares accounted for 4.06% of the company's total share capital. The highest transaction price of the shares repurchased was 14 yuan/share, and the minimum transaction price was 9.07 yuan/share. This repurchase complies with the requirements of the company's share repurchase plan and related laws and regulations .
Chenguang Biology (300138.SZ): Overseas marigold planting bases have a cost advantage over domestic production areas
Gelonghui, April 19 | Chenguang Biotech (300138.SZ) said on the investor interactive platform that the company's overseas marigold planting base has a cost advantage over domestic production areas. By expanding the area of overseas planting bases, it is possible to reduce the cost of the company's lutein products and enhance the market competitiveness of the products.
No Data